CL2025001156A1 - Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer. - Google Patents

Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.

Info

Publication number
CL2025001156A1
CL2025001156A1 CL2025001156A CL2025001156A CL2025001156A1 CL 2025001156 A1 CL2025001156 A1 CL 2025001156A1 CL 2025001156 A CL2025001156 A CL 2025001156A CL 2025001156 A CL2025001156 A CL 2025001156A CL 2025001156 A1 CL2025001156 A1 CL 2025001156A1
Authority
CL
Chile
Prior art keywords
cldn4
bispecific antibody
signaling inhibitor
treatment
combination
Prior art date
Application number
CL2025001156A
Other languages
English (en)
Spanish (es)
Inventor
Sato Masahito
HIROUCHI Keita
Kikuchi Aya
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CL2025001156A1 publication Critical patent/CL2025001156A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2025001156A 2022-10-19 2025-04-16 Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer. CL2025001156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022167362 2022-10-19

Publications (1)

Publication Number Publication Date
CL2025001156A1 true CL2025001156A1 (es) 2025-05-23

Family

ID=90737914

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001156A CL2025001156A1 (es) 2022-10-19 2025-04-16 Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.

Country Status (10)

Country Link
EP (1) EP4606384A1 (https=)
JP (1) JP7730432B2 (https=)
KR (1) KR20250089513A (https=)
CN (1) CN119997975A (https=)
AU (1) AU2023365438A1 (https=)
CL (1) CL2025001156A1 (https=)
IL (1) IL319946A (https=)
MX (1) MX2025004457A (https=)
TW (1) TW202426503A (https=)
WO (1) WO2024085166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
AU2015244814B2 (en) * 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
EP3445788B1 (en) * 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
AU2022262542A1 (en) * 2021-04-22 2023-11-02 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody

Also Published As

Publication number Publication date
MX2025004457A (es) 2025-05-02
IL319946A (en) 2025-05-01
AU2023365438A1 (en) 2025-04-17
EP4606384A1 (en) 2025-08-27
KR20250089513A (ko) 2025-06-18
JP7730432B2 (ja) 2025-08-27
JPWO2024085166A1 (https=) 2024-04-25
WO2024085166A1 (ja) 2024-04-25
TW202426503A (zh) 2024-07-01
CN119997975A (zh) 2025-05-13

Similar Documents

Publication Publication Date Title
CL2025001156A1 (es) Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
CL2024000318A1 (es) Compuestos de pirazolopiridinona
PH12014500965A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
AR128108A1 (es) Indoles, indazoles y análogos relacionados para inhibir yap / taz-tead
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
JOP20230261A1 (ar) جسم مضاد ثنائي النوعية لـ cldn4/cd137
MX2024012620A (es) Regimenes de dosificacion para agentes anti-cd19 y usos de los mismos
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
AR066690A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapeuticos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
MX2023011931A (es) Materiales y métodos para mejorar la ingenieria de células t de memoria similares a células madre.
AR128110A1 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead
CO2025004806A2 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y usos de los mismos
MX2022009041A (es) Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
CL2023002484A1 (es) Conjugados de arni y usos de los mismos
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CL2025001708A1 (es) Esquema de dosificación de una dispersión sólida de un inhibidor de her2
AR121013A1 (es) Anticuerpos anti-cd40 y composiciones
MX2023004899A (es) Direccionamiento de src-3 en celulas inmunitarias como un inmunomodulador terapeutico para el tratamiento de cancer.
MX2022006891A (es) Terapia combinada con liv1-adc y antagonista de pd-1.